Top life sciences deals of 2025 show a market chasing scale
CURRENT FULL VERSION: PharmaShots’ new Top 20 Life Sciences Deals of 2025 ranking offers a useful snapshot of how biopharma dealmaking evolved over the past year: not necessarily busier, but bigger. According to the PharmaShots summary published with DealForma data, the year’s biggest transactions were led by Jiangsu Hengrui Pharma’s up-to-$12.5 billion pact with GSK, followed by Innovent Biologics’ approximately $11.4 billion deal with Takeda, and BioNTech’s roughly $11.1 billion BNT327 alliance with Bristol Myers Squibb. The throughline is clear: companies spent 2025 chasing high-value programs and technology platforms with the potential to reshape core pipelines. (linkedin.com)
That marks a shift from the more cautious tone entering the year. McKinsey wrote in February 2025 that life sciences M&A appeared “primed for an increase” after a softer 2024, driven by pent-up demand, dry powder, and pipeline needs. By year-end, IQVIA’s 2025 annual review said that overall publicly disclosed deal activity had actually declined 12% year over year, while M&A value surged and nine acquisitions topped $10 billion. In other words, the rebound happened less through volume than through selectivity and scale. PharmaShots’ separate Top 20 Healthcare IPOs of 2025 report points to the same broader financing backdrop: investor confidence remained strong in biotech, medtech, digital health, and AI-enabled healthcare, but capital was concentrated in larger raises, led by Medline Industries at $7.2 billion, with Caris Life Sciences and Lumexa Imaging next in line. (mckinsey.com)
PharmaShots’ ranking reflects that concentration. Its article says platform technologies dominated the landscape, with buyers seeking bispecific antibodies, siRNA, gene editing, and AI-enabled discovery capabilities rather than just isolated assets. The BioNTech-Bristol Myers Squibb transaction is a strong example: BMS said it would pay $1.5 billion upfront and $2 billion in non-contingent anniversary payments through 2028 to co-develop and co-commercialize BNT327, with BioNTech also eligible for up to $7.6 billion in additional milestones. That structure shows how large pharma continued to balance urgency with risk-sharing. The same preference for technology-enabled, scalable platforms was visible in the IPO market, where PharmaShots said AI-driven drug discovery, precision medicine, and digital care platforms attracted some of the largest inflows. (linkedin.com)
The Hengrui-GSK agreement tells a similar story, with an added geographic angle. Reporting on the deal shows GSK committed $500 million upfront for rights tied to an experimental COPD medicine and options on additional Hengrui programs, with the total package potentially reaching about $12 billion to $12.5 billion depending on milestones and exercised options. Industry coverage framed the transaction as another sign that Western drugmakers are increasingly looking to Chinese biopharma for external innovation, especially when they want clinical-stage assets without building everything in-house. That cross-border theme also showed up outside therapeutics; for example, PharmaShots’ IPO roundup included Shenzhen Edge Medical, a China-based surgical robotics company, among the year’s notable public offerings. (cooley.com)
Industry commentators broadly described 2025 as a year of bigger bets on more mature science. IQVIA said companies prioritized “quality over quantity” and focused on late-stage, clinically validated assets. Pharmaceutical Technology, citing EY Life Sciences global deals leader Subin Baral, reported that average deal size had climbed to roughly $1.9 billion to $2 billion, materially above 2024 levels. Nature, in its midyear biopharma deal watch, also pointed to a strong first half for high-value transactions, again with DealForma data in the background. PharmaShots’ own news coverage filled in some of that picture: CVC Capital Partners proposed a roughly €10.9 billion acquisition of Recordati, valuing the company at €52 per share and potentially taking it private, while Eli Lilly agreed to acquire Centessa Pharmaceuticals in a deal valued at about $7.8 billion to add sleep medicine and neuroscience assets including cleminorexton and ORX142. Taken together, those assessments suggest the PharmaShots ranking is less an outlier than a concise expression of a wider market pattern. (iqvia.com)
Another important piece of the 2025 story is who has capital to keep doing these transactions. PharmaShots reported that Blackstone closed Blackstone Life Sciences VI at its $6.3 billion hard cap, making it the largest life sciences vehicle and about 40% larger than its predecessor. Blackstone said the BXLS platform, launched in 2018, had about $15 billion in assets under management as of Q4 2025 and had committed roughly $2 billion over the prior 12 months through partnerships with companies including Merck, Teva, Alnylam, and Novartis. That matters because specialist funds like this can keep supporting royalty deals, structured financings, and late-stage development programs even when broader markets are uneven. (linkedin.com)
Why it matters: For veterinary professionals, the direct relevance is strategic rather than clinical. Companion animal and livestock medicine don’t usually sit at the center of these headline biopharma deals, but the same capital markets, manufacturing networks, platform technologies, and licensing norms often ripple into animal health. When large human-health companies put more money behind oncology, immunology, RNA technologies, AI discovery, neuroscience, rare disease, and biologics platforms, that can influence where veterinary innovation funding flows next, what kinds of startups get backed, and how quickly translational technologies move toward animal applications. The IPO data adds another signal: investors are still willing to fund healthcare stories, but they appear to prefer scaled, differentiated, tech-enabled businesses over earlier, narrower plays. It also matters for clinics and health systems serving pet parents because broader life sciences consolidation can affect pricing power, supply chains, and competition for specialized talent. These are indirect effects, but they’re real. (linkedin.com)
What to watch: In 2026, watch for three things: whether deal volume stays muted while values remain elevated; whether take-private, structured-financing, and platform-led transactions continue alongside traditional licensing, as seen in the Recordati proposal, the Centessa acquisition, and Blackstone’s expanding life sciences fund; and whether China-originated licensing and technology sourcing continue to gain share in global biopharma partnerships. For veterinary medicine specifically, it will be worth watching whether the emphasis on de-risked platform science, AI-enabled tools, and later-stage assets begins to show up more visibly in animal health transactions, diagnostics, and therapeutics. If 2025 was the year of selective megadeals, the next question is whether that capital discipline spreads downstream into adjacent sectors, including veterinary medicine. (iqvia.com)